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Abstract
Chronic kidney disease (CKD) and coronary artery disease (CAD) are conditions that, 
when present together, is considered a high-risk feature. Despite the high prevalence, 
few studies are dedicated to studying CAD specifically in individuals with CKD, and it is 
a common exclusion criterion in most trials. This fact leads to gap in the evidence for the 
management of CAD, which, sometimes, results in undertreatment of CKD patients. In 
this chapter, authors present peculiarities related to CAD among patients with CKD from 
physiopathology to diagnostic and therapeutic decisions. An evidence-based approach 
was used to explore this high-risk subset of CAD patients.
Keywords: chronic kidney disease, coronary artery disease, atherosclerosis, coronary 
artery bypass graft, percutaneous coronary intervention
1. Background
The association between chronic kidney disease (CKD) and coronary artery disease (CAD) 
has been the subject of numerous studies recently. Not only because of the frequent associa-
tion between the two entities, but also because of the aggregate risk when both conditions are 
present in the same individual.
Despite the high prevalence, few studies are dedicated to studying CAD specifically in indi-
viduals with CKD. In fact, CKD, especially in its final stages, is a common exclusion criterion 
in large studies. This fact resulted in a gap in the evidence for the management of CAD, 
which, sometimes, results in undertreatment of CKD patients.
This chapter aims to explore the association between CAD and CKD, approaching from 
pathophysiology to available evidence for the treatment of these conditions.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Coronary atherosclerosis and renal failure
Another scenario where there is a profound interaction between renal failure and the cardio-
vascular system is with regard to coronary atherosclerosis. It is known that chronic kidney 
disease adds risk to coronary events. The relationship between renal disease and cardiovas-
cular mortality can be found even in the early stages of disease [1] and increases as kidney 
function deteriorates [2] (see Table 1 for the stages of CKD according to the National Kidney 
Foundation KDOQI Clinical Practice Guidelines [3]). It is also known that the population with 
CAD and CKD has higher mortality regardless of the treatment used for coronary disease [4].
Several epidemiological studies have demonstrated that CKD is an independent risk factor 
for cardiovascular events.
The Framingham Heart Study was one of the first to associate chronic kidney disease with 
cardiovascular events in the general population. Of the 6233 study participants, stage 2 CKD 
was found in 246 men and 270 women. Of these, 81% were not diagnosed with cardiovas-
cular disease at the start of the study. After 15 years of follow-up, there was a tendency for 
a higher incidence of cardiovascular events in the male population with stage 2 CKD [5]. 
Data from the Atherosclerosis Risk in the Communities study also confirm an increase in 
the risk of cardiovascular events in this same population [6]. When GFR is considered as a 
continuous variable, this study points to a 5–6% increase in cardiovascular risk for each loss 
of 10 mL/min/1.73 m2 of GFR. Go and colleagues also demonstrated, in a cohort study of 
1,120,295 patients, comprised of approximately 9.6% of diabetics and 6.3% of CAD patients, 
a risk of death of about 1.2 times higher associated with an GFR 45–59 mL/min/1.73 m2 when 
compared to those with GFR ≥60 mL/min/1.73 m2 [7]. There was a growing risk as the lowest 
GFR was considered, culminating with a relative risk of about 5.9 in those patients with RFG 
<15 mL/min/1.73 m2.
There is also a worse prognosis associated with renal failure in populations with established 
heart disease. The Valsartan in Acute Myocardial Infarction Trial (VALIANT) looks at the 
influence of GFR, even in its early stages, in a population at high risk for cardiovascular 
Stages GFR (mL/min/1.73 m2) CKD
0 >90 Risk group for CKD. Absence of renal injury
1 >90 Normal renal function. Presence of kidney damage
2 89–60 Discrete or functional CKD
3 59–30 Moderate or laboratory CKD
4 29–15 Severe or clinical CKD
5 <15 Terminal or pre-dialytic CKD
Table 1. Staging and classification of CKD.
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events [8]. This study accompanied patients after acute myocardial infarction complicated 
by systolic ventricular dysfunction or symptoms of congestive heart failure (CHF) who were 
randomized to either valsartan, captopril or both. After adjusting for the received treatment 
and comorbidities, a risk of 1.14 times greater risk for cardiovascular death was found in 
patients with an GFR of 60–74 mL/min/1.73 m2 (95% CI 1.02–1.27) and 1.10 times for combined 
events (cardiac mortality, re-infarction, CHF and stroke) when compared to the population 
with normal renal function. A factor that may have contributed to these findings is that the 
CKD population was undertreated when compared to the population with normal renal func-
tion, receiving invasive stratification (27.5% vs. 34.7%) and beta-blockers (71.9% vs. 74.7%) to 
a lesser extent than those with preserved renal function.
2.1. Mechanisms of cardiovascular complications in CKD
As previously described, kidney disease, even in its early stages, poses an increased risk of 
cardiovascular events. Even initial lesions such as a discrete fall in GFR or microalbuminuria 
(including patients with normal GFR) are associated with increased cardiac mortality, AMI 
or stroke. The main pathophysiological mechanism involved in this complex relationship 
appears to be endothelial dysfunction.
2.1.1. Endothelial dysfunction
Endothelial dysfunction is one of the initial events of the so-called atherosclerotic gait. It is 
present in both small and large vessels. Reducing the bioavailability of nitric oxide (NO) is 
one of the main mechanisms involved in endothelial dysfunction in patients with GFR. In 
this context, it is important to highlight the role of asymmetric dimethyl arginine (ADMA), 
which is derived from protein catabolism and competitive inhibitor of NO synthase produced 
mainly in the endothelium, the heart and the smooth cells and is clarified by the kidneys. 
When in high concentrations, as in individuals with GFR, it blocks the entry of L-arginine at 
the cellular level, leading to a reduction in NO synthesis. This leads to increased peripheral 
vascular resistance, intimal hyperplasia of the vessels and consequent increase in blood pres-
sure with remodeling of the same. Recent studies have pointed to ADMA as an independent 
marker of cardiovascular risk in individuals with CAD [9].
2.1.2. Albuminuria
The correlation between macroalbuminuria and microalbuminuria with endothelial dys-
function measured in peripheral vessels is something that has been demonstrated and is a 
consequence of glomerular hyperfiltration. Thus, albuminuria has been identified not only 
as a consequence of the renal aggression that precedes the fall of GFR, but also as powerful 
marker of cardiovascular risk. Like GFR, albuminuria increases cardiovascular risk even at 
minimal levels. This risk increases as the albuminuria level rises, defined as normal albumin 
excretion (<30 mg/g), to microalbuminuria (30–300 mg/g) and, finally, with macroalbumin-
uria (>300 mg/g).
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Several studies have demonstrated the role of albuminuria as a marker of cardiovascular risk. 
The Irbesartan Diabetic Nephropathy Trial (IDNT) studied 1715 subjects with type 2 DM, 
hypertension and macroalbuminuria, randomizing them to receive irbesartan, amlodipine 
or placebo. In a post-hoc analysis of Anavekar [10], univariate analysis showed an increase in 
cardiovascular risk proportional to the value of albuminuria. Multivariate analysis confirmed 
albuminuria as an independent risk factor. The (Reduction of End Points in NIDDM with 
Angiotensin II Antagonist Losartan (RENAAL) study [11] showed similar results, demonstrat-
ing a 1.92-fold higher risk of cardiovascular events in the group with albuminuria >3000 mg/g 
when compared to the dose group <1500 mg/g. The HOPE [12] study got a RR of 1.83 for 
cardiac death and 1.61 for the combined outcome of AMI or stroke in the population with 
albuminuria >17.7 mg/g. In addition, subsequent analyzes of HOPE suggest that albuminuria 
as low as 4.4 mg/g already translates into increased cardiovascular risk, suggesting that it 
behaves as a continuous variable [13].
2.1.3. Systemic arterial hypertension
Hypertension is present in most patients with CKD and atherosclerotic disease. The activa-
tion of the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system and 
sodium retention plays an important role in the development of hypertension. Recently, 
renalase, a regulator of cardiac function and blood pressure produced by the kidney, has 
been discovered. This regulator metabolizes catecholamines and has hypotensive action. Its 
absence may be responsible for adrenergic hyperreactivity leading to endothelial dysfunction 
and cardiac and vascular remodeling [9].
The activation of RAAS occurs in several ways in kidney disease. Angiotensin II stimulates 
NAD (P) H oxidase, leading to superoxide anion formation and contributing to endothelial 
dysfunction and cardiac remodeling. In addition, when angiotensin II stimulates the AT 1 
receptor, there is generation of reactive oxygen species (ROS) with release of inflammatory 
mediators, including cytokines, adhesion molecules, PAI-1 (plasminogen activator inhibitor-1), 
among others. These events eventually promote the progression of atherosclerosis.
2.1.4. Inflammation
Atherosclerosis has been considered as an inflammatory condition. CKD patients are known 
as ‘inflamed patients’ since we have evidence of measurable inflammatory markers such as 
C-reactive protein (CRP), fibrinogen, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-
alpha), factor VIIc, factor VIIIc, plasmin-antiplasmin complex, D-dimer, E-selectin, VCAM-1 
and ICAM1, as well as the deleterious effects of the inflammatory process in this population 
[9]. The poor nutrition of these patients, evidenced by low levels of albumin, pre-albumin and 
transferrin, has been suggested as a possible mechanism of activation of the inflammatory 
process. In addition, oxidative stress, the accumulation of modified molecules after synthesis, 
nonenzymatic glycosylation products or other products normally cleansed by the kidney also 
have their role in triggering inflammation [9]. Consequently, we have alterations in the endo-
thelium and lipoproteins leading to accelerated atherosclerosis.
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CRP has been particularly studied in the chronic kidney population, being found at higher 
levels in the terminal CKD population than in the normal population. CRP has been shown to 
be an excellent marker of cardiovascular risk in this population [14, 15].
The inflammation also seems to be related to the vascular calcification process, so common 
in patients with CKD, markedly in those in advanced stages of the disease. Calcification may 
be present in the medial layer of vessels, smooth muscle cells, medial muscular arteries and 
valvular system. As calcification progress, the capacitance of the arterial vessels is reduced, 
promoting the progression of systemic arterial hypertension (SAH) and left ventricular hyper-
trophy (LVH). The mechanisms involved in the CKD calcification process are complex and 
include the passive precipitation of Ca and P in the presence of high concentrations of these 
ions in the extracellular, in addition to the effect of inducers of osteogenic transformation, 
formation of hydroxyapatite and deficiency of calcification inhibitors such as osteoprotegerin 
and fetuin-A. In addition, high levels of leptin, common in patients with CKD due to reduced 
GFR, can induce calcification via hypothalamic receptors, stimulating osteoblastic beta-adren-
ergic receptors, generating ROS and inducing bone morphogenetic protein-2 (BMP-2). BMPs 
are regulators of bone formation, acting on receptors (BMPRs) that modulate gene expression. 
BMP-2 and BMP-4 are promoters of calcification, while BMP-7 behaves as an inhibitor of this 
process. BMP-7 is expressed mainly in the kidney and its reduction is proportional to the loss 
of renal function (Figure 1) [9].
Figure 1. Atherosclerosis and calcification in renal failure. Extracted from Mizobuchi et al. [35].
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3. Particularities in the diagnosis and treatment of CAD in patients 
with renal insufficiency
The incidence of coronary disease in the CKD population is high. Gowdak and colleagues 
observed a 47% incidence of angiographically significant CAD among patients with terminal 
CKD awaiting renal transplantation [16]. Interestingly, even in the population without tradi-
tional risk factors (SAH, DM, obesity, dyslipidemia and smoking), the observed incidence of 
CAD was 26%, and may reach 100% among those with all risk factors mentioned above.
The best method to investigate or stratify CAD in this population is still a matter of dispute. 
The presence of endothelial dysfunction, LVH, hypertension and volume overload in chronic 
renal patients should be considered when choosing the best method.
Some studies have considered that a more aggressive strategy should be used, since the non-
invasive methods do not have good accuracy in the prediction of events in this population, 
especially in those with terminal CKD. In an attempt to validate a strategy for diagnosis of 
significant CAD in a population of chronic dialysis patients, a study conducted at the Heart 
Institute of the Hospital das Clínicas of the USP Medical School (InCor-HCFMUSP) confirms 
that the documented coronary angiography and the presence of DM were good predictors of 
cardiovascular events. The sensitivity, specificity and positive and negative predictive values 
of myocardial scintigraphy with dipyridamole were 70, 74, 69 and 71%, respectively. It is 
worth noting that scintigraphy did not diagnose CAD in a significant number of patients with 
CAD confirmed by coronary angiography [16, 17]. These data confirm that the invasive strat-
egy remains the gold standard in the diagnosis and stratification of risk in this population. 
It is important to remember that the use of iodinated contrast (especially in the population 
with discrete to moderate CRF) may worsen the renal function of these individuals, and the 
need for hemodialysis in cases of contrast-induced nephropathy is not uncommon. This, in 
addition to being an invasive, more expensive and less available method, does not authorize 
us to indicate routine coronary angiography for patients with CKD in the investigation and/
or stratification of CAD. Clinical judgment should weigh the risk factors already mentioned 
to select the population that will benefit most from the invasive examination.
The use of new methods for the diagnosis of CAD, such as coronary angiotomography, 
calcium score and magnetic resonance imaging has also been studied in this population. 
In a recently published study, the calcium score applied to a population of renal transplant 
candidates had a good correlation with angiographic CAD for diagnosis, as well as being a 
good predictor of cardiovascular events when above 400 Agatston [18]. Magnetic resonance 
imaging has its importance mainly in the evaluation of previous infarctions, ischemia and 
myocardial viability in this population [19].
4. Treatment of CAD in patients with CKD
Treatment of coronary disease is based on optimized medical therapy associated or not with inter-
ventional procedures (surgical revascularization or angioplasty). The population with CAD and 
CKD has peculiarities that should not be forgotten when choosing the best therapeutic strategy.
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The population of chronic renal failure with CAD is certainly a subgroup that benefits as 
much as possible from full clinical management because it is a group of patients with multiple 
comorbidities and an accelerated atherosclerosis [20]. In spite of this recommendation, the 
population with renal dysfunction is frequently undertreated, which surely contributes to the 
worse prognosis of this special population [21].
Interventional therapy in patients with chronic kidney disease with CAD seems to be ben-
eficial in some situations, especially when we consider their high atherosclerotic load and 
angiographic complexity.
A retrospective study by Reddan, conducted at Duke University, analyzed 4584 patients 
with CAD who underwent clinical treatment, percutaneous coronary intervention (PCI) or 
myocardial revascularization (CABG), who were stratified according to GFR, followed and 
evaluated for cardiovascular events. In this study, a benefit of percutaneous treatment over 
clinical treatment was observed in the population with mild to moderate CRF, but not among 
those with terminal CKD. When comparing myocardial revascularization surgery with medi-
cal treatment, we observed that, curiously, the benefit of surgery is greater as the severity of 
renal failure progresses [4].
In our setting stands out a subanalysis of MASS II [22], conducted by Lopes and collaborators 
at InCor - HCFMUSP. In this publication, 611 patients from the original study, randomized to 
medical treatment, PCI or CABG, were stratified by GFR in 3 categories (RFG ≥ 90, between 
89 and 60 or between 59 and 30 mL/min/1.73 m2) and classified as with normal renal function 
(n = 112/18%), mild (n = 349/57%) or moderate (n = 150/25%), respectively. The results point 
to a higher mortality among the population with moderate CRF, compared to the other two 
groups. In addition, it was observed that among patients with mild CRF, patients submitted to 
surgery had a higher survival rate free of cardiovascular events and lower mortality in 5 years 
compared to the population submitted to angioplasty or in exclusive medical treatment.
Lima and collaborators evaluated in a registry-type study 763 diabetic patients with CAD 
of the MASS group stratified according to renal function and followed for about 5 years. Of 
note is the high rate of CKD patients when applied clearance estimated by Cockcroft-Gault, 
with almost 65% of patients with some degree of CKD having clearance <90 mL/min. Even in 
an exclusively diabetic population, the presence of CKD was associated with higher mortal-
ity regardless of the treatment received, with survival rates of 91.1%, 89.6% and 76.2% for 
the preserved function, mild and moderate CKD, respectively (p = 0.001). When compared 
to the drug treatment, the surgical treatment was associated with lower combined event 
rates in the stratum with discrete CKD (86.2% versus 65.7% for CABG and TM respectively, 
p < 0.001) and additional revascularization in all function strata studied.
4.1. Interventional treatment in patients with end-stage CKD
This is a population where, despite the interventional therapy chosen, there is a higher risk 
of morbidity and mortality when compared to the general population. A patient undergoing 
CABG has a 4.4-fold greater risk of in-hospital death, a 3.1-fold increase in mediastinitis, and 
a 2.6-fold increase in stroke than a nondialysis patient. Some studies point to the safety of 
angioplasty in this population, especially in single-vessel patients [23]. However, when we 
compare angioplasty with surgical revascularization, it seems to bring greater cardiovascular 
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protection to these patients [24]. This can be attributed to a higher rate of restenosis in this 
population, which is derived from a close association with diabetes mellitus, accelerated ath-
erosclerosis and vascular calcification [25].
Several studies in chronic coronary disease have evaluated the performance of the subpopula-
tion of chronic renal patients in their trials. In a post-hoc analysis of the ARTS study [26], 142 
patients with moderate CKD with multiarterial CAD were randomized to receive surgery 
or angioplasty and followed for 5 years. Regardless of the revascularization method chosen, 
patients with moderate CRF had more cardiovascular events (death, stroke, nonfatal AMI or 
additional revascularization) than the population with mild or normal renal function. When 
we compared the strategies, we observed that there was no significant difference in mortality 
(RR: 1.18, 95% CI: 0.51–2.72, p = 0.81), but a greater number of events combined in the angio-
plasty group (RR: 1.56, 95% CI: 1.03–2.37, p = 0.04), mainly due to additional revasculariza-
tions (29% vs. 9.6% p = 0.005).
The BARI study [27] evaluated 3608 patients (randomized and from the registry), stratifying 
them into two groups: with and without CRF, which was defined as baseline serum creatinine 
greater than 1.5 mg/dL. Of the total, 1517 patients were submitted to surgery and 2091 to angio-
plasty. Of these, 76 patients were considered to have chronic renal failure. This population 
was older and had a higher proportion of hypertensive and diabetic patients. Among patients 
undergoing PCI, chronic kidney disease had a higher incidence of in-hospital mortality and 
cardiogenic shock. In addition, this population was more susceptible to the presence of angina, 
hospitalizations due to cardiac reasons and less time for additional revascularization compared 
to the normal population. In 7 years, the population with CKD had a higher incidence of general 
(RR: 2.2, p < 0.001) and heart (RR: 2.8, p < 0.001) than the population with normal renal function.
Although we consider the benefit of pharmacological stents on conventional stents with 
regard to the lower incidence of restenosis, recent studies comparing pharmacological stents 
with CABG in this population show a greater benefit of the latter, especially at the expense 
of lower rate of additional revascularization [28]. A recent study by Marui and colleagues 
from the CREDO-Kyoto registry demonstrated that in 388 patients with dialytic CKD, similar 
incidences of general and cardiac death were observed when CABG compared with PCI in a 
long-term follow-up. The latter strategy, however, was associated with higher rates of AMI 
and additional revascularization [29].
In the post-hoc analysis of the FREEDOM study [30], comparison of interventional strategies 
among diabetic patients with CAD in the presence of renal dysfunction defined by estimated 
clearance <60 mL/min did not demonstrate superiority of CABG on PCI with first-generation 
pharmacological stent at MACCE rate at 5-year follow-up.
Charytan et al. [31] in a collaborative study including 10 randomized prospective studies of 
3993 subjects demonstrated similar survival rates at 5 years when patients with CKD class 3–5 
underwent CABG or PCI (HR 0.99, CI 0.67–1.46). However, AMI-free survival among patients 
with CKD class 3–5 was higher among those undergoing surgical treatment (HR: 0.49; CI: 
0.29–0.82). Consistent with other studies, CABG was associated with lower rates of additional 
revascularization than PCI, regardless of the renal function stratum considered.
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Recently, a meta-analysis by Bundhun’s et al. [32] included 18 studies involving a larger 
number of patients (n = 69,456, 29,239 underwent CABG and 40,217 underwent PCI). This 
present analysis observed a benefit of CABG in reducing mortality when compared to PCI 
in long-term follow-up only (OR: 0.81, 95% CI: 0.70–0.94, p = 0.007 for nondialytic, OR: 
0.81, 95% CI: 0.69–096, P = 0.01 for dialytic). It is also worth mentioning a benefit in reduc-
ing additional revascularizations among those submitted to CABG in almost all studies 
that included this outcome. Of note, however, is the heterogeneity of the included studies, 
with different definitions for CKD, in addition to follow-up times ranging from 1 month 
to 8 years.
Off-pump CABG was also evaluated in some studies because of the theoretical benefit of a less 
aggressive procedure than on-pump CABG. These studies have demonstrated a lower need for 
blood products and dialysis in the postoperative period, shorter hospital stay in intensive care 
and mechanical ventilation, but with no difference in mortality in the medium term [24, 33]. 
Consistent with these previous results, recently published data from the Coronary Artery 
Bypass Grafting Surgery Off-pump Revascularization Study, comparing on-pump versus 
off-pump CABG, showed a reduced risk of perioperative acute renal injury associated with 
off-pump CABG. In spite of this, no renal protection was observed at the 1-year follow-up 
associated with this surgical strategy [34].
5. Final considerations
CKD has a negative impact on the prognosis of individuals with CAD regardless of the treat-
ment. There are no peculiarities in the indication of revascularization in this population, and 
attention must be paid to the greater clinical and angiographic severity of this population. 
The drug treatment should be applied considering the potential limitations of the use of some 
classes among those with terminal CKD, however, avoiding at all costs under-treatment. 
There is still no consensus on the best therapeutic strategy for CAD (e.g. interventional ver-
sus conservative; PCI versus CABG) for those with CKD. The studies are heterogeneous and 
almost completeness formed by observational records, post-hoc analyses of large trials or 
meta-analyses. In spite of this, some clarity seems to emerge from these publications: (1) the 
greater the angiographic severity/severity of CKD, the greater is the benefit of surgical revas-
cularization; (2) in the subpopulations with discrete/moderate CKD, there is no clear evidence 
of surgery on the other treatments; and (3) surgery is associated with less need for additional 
revascularization independently of the status of renal function, which suggests that this bene-
fit is associated with the revascularization method itself, rather than the patient’s renal status.
We await the results of the ISCHEMIA-CKD study (ClinicalTrials.gov Identifier: 
NCT01985360), designed to study patients with documented (at least moderate) ischemia 
and severe renal dysfunction (GFR <30 or on dialysis) randomized to an initial strategy of 
coronary angiography and interventional treatment plus optical medical therapy or optimal 
medical therapy alone. Its results will surely bring answers to pertinent questions not yet 
answered in this common clinical scenario.
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